塞来昔布对不同程度骨关节炎患者TNF-α、IL-1β及PGE-2的影响

Effect of G2 Celecoxib on TNF-α, IL-1β and PGE-2 in patients with different degree of osteoarthritis

目的探讨塞来昔布对不同程度骨关节炎患者肿瘤坏死因子(TNF-α)、白细胞介素(IL-1β)及前列腺素E2(PGE-2)的影响。方法选取自2014-03—2015-03诊治的骨关节炎124例,根据患者的影像学检查结果和临床表现分为轻度组、中度组和重度组。轻度组45例,中度组48例,重度组31例,所有患者口服塞来昔布。比较治疗前、治疗4周后和治疗8周后关节液中TNF-α、IL-1β、PGE-2含量,以及疼痛视觉模拟评分(VAS)。结果 3组治疗前关节液中TNF-α、IL-1β、PGE-2含量及VAS评分差异有统计学意义(P<0.05),且随着骨关节炎程度加重,各炎症因子含量、VAS评分逐渐升高。治疗4、8周后,所有患者关节液中TNF-α、IL-1β、PGE-2含量及VAS评分均下降,差异有统计学意义(P<0.05);且中度组下降程度最大,轻度组次之,重度组最小。结论塞来昔布可以有效抑制炎性因子TNF-α、IL-1β及PGE-2的生成,对抗炎症反应,缓解疼痛,对轻、中度骨关节炎患者效果更佳。

Objective To investigate the effects of G2 Celecoxib on TNF-α, IL-1β and PGE-2 in patients with different degree of osteoarthritis. Methods One hundred and twenty-four patients with osteoarthritis who were diagnosed osteoarthritis from March 2014 to March 2015 were chosen and divided into mild group, moderate group and severe group according to the clinical presentation and image studies. There were 45 cases in mild group, 48 cases in moderate group and 31 in severe group and all the patients aeeepted G2 Celeeoxib therapy orally. The levels of TNF-α, IL-1β and PGE-2 and VAS of before therapy, 4-week therapy and 8-week therapy were compared. Results The levels of TNF-α, IL-1β and PGE-2 and VAS were significant differences among the three groups before therapy （P 〈0.05） and the levels of inflammatory faetors and VAS were higher with more severer osteoarthritis. After 4-week therapy and 8-week therapy, the levels of TNF-α, IL-1β and PGE-2 and VAS of all patients reduced signifieandy（P 〈0.05） and moderate group had the best results followed by mild group and severe group. Conclusion G2 Celeeoxib can effectively inhibit inflammatory factors TNF-α, IL-1β and PGE-2 in different osteoarthritis period. Overall it has positive effect in patients with mild and moderate osteoarthritis.